Waters Corporation (NYSE: WAT) today announced that the BD BACTEC FXI Culture System has received U.S. Food and Drug Administration (FDA) 510(k) clearance. This clearance enables commercialization in the U.S. and provides a new option for laboratories seeking a fully automated blood culture system designed to improve the speed, consistency, and accuracy of sepsis and bloodstream infection diagnostics in modern microbiology laboratories.

Against the background of an increasingly aging global population, the incidence of thrombotic and hemostatic diseases, including cardiovascular diseases, remains high.

Against the background of an increasingly aging global population, the incidence of thrombotic and hemostatic diseases, including cardiovascular diseases, remains high.

Against the background of an increasingly aging global population, the incidence of thrombotic and hemostatic diseases, including cardiovascular diseases, remains high.

China has been engaged in the R&D and manufacturing of semi-automatic coagulation analyzers for over a decade, and based on the data from the website of the NMPA, in 2024 and 2025 (as od 15 August), a total of 2 instruments from 2 manufacturers have obtained registration certificates...

Conventional thrombosis and hemostasis diagnostic applications are mainly concentrated on screening for bleeding disorders and diagnosis of bleeding origins, with a relatively narrow scope of application and relatively poor accuracy.

Diasorin today announces that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the company’s new LIAISON PLEX® Yeast Blood Culture (BCY) Assay, the second molecular multiplexing panel on the LIAISON PLEX® system.

Building on 80 years of expertise engineering cold storage lab equipment, Thermo Fisher Scientific today introduces its newest line of high performance, ultra-low temperature (ULT) freezers. With enhancements to performance, user experience and energy efficiency, the Thermo Scientific™ TSX™ Universal Series ULT Freezers seamlessly adapt to scientists’ workflows across a variety of lab settings, marking a new era in performance, reliability, and sustainability.

Diagnostic test maker Technoclone on Tuesday said it has secured US Food and Drug Administration de novo marketing authorization for a test that is used to aid the diagnosis of a rare, life-threatening blood-clotting disorder.

DiaSorin has received the US Food and Drug Administration’s 510(k) clearance for its LIAISON PLEX platform and the accompanying LIAISON PLEX Respiratory flex assay.